Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628656 | 0.95 | PTGER2 (0.42) | PTGER2PTPN7LTB4R | |
| SCHEMBL1471097 | 0.84 | PTGER2 (0.49) | PTGER2LTB4RPTGER4PTGER3 | |
| SCHEMBL5725268 | 0.82 | PTGER2 (0.46) | PTGER2LTB4R | |
| SCHEMBL2162320 | 0.77 | LTB4R (0.43) | PTGER2RECQLTDP1KDM4EMEN1 | |
| SCHEMBL1471697 | 0.76 | FFAR1 (0.43) | PTGER2RECQLTDP1KDM4EMEN1 | |
| SCHEMBL5725576 | 0.76 | CNR2 (0.51) | PTGER2LTB4RPTGER4PTGER3 | |
| SCHEMBL5725463 | 0.75 | CA12 (0.44) | — | |
| SCHEMBL1471278 | 0.74 | CNR2 (0.53) | PTGER2TDP1ALDH1A1KMT2A | |
| SCHEMBL1471108 | 0.72 | ALDH1A1 (0.47) | PTGER2TDP1ALDH1A1KMT2APTGER4 | |
| SCHEMBL4628658 | 0.72 | LTB4R (0.44) | PTGER2PTPN7LTB4RPTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917238-A2 | SULFONAMIDES | Allergan, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | claimed |
| WO-2007024860-A2 | SULFONAMIDES | ALLERGAN, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-7915316-B2 | Sulfonamides | ALLERGAN, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915316-B2 | Sulfonamides | ALLERGAN, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915316-B2 | Sulfonamides | ALLERGAN, INC (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1917238-A2 | SULFONAMIDES | Allergan, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2007024860-A2 | SULFONAMIDES | ALLERGAN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142471-A1 | SULFONAMIDES | CRYZ, QDPR, GLRX3 | PTGER2 1557/4885RECQL 687/4885TDP1 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.